IMUGENE LIMITED — Director's Dealing 2015

Feb 1, 2015

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity: Imugene Limited

ACN:
009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Charles Walker
Date of appointment	30/1/15

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

25,000,000 Ordinary Shares.

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Employment Agreement / Share Purchase & Loan Agreement
Nature of interest	Direct
Name of registered holder (if issued securities)	Securities not issued. Issue of shares subject to achievement of performance hurdles.

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002

Appendix 3X Initial Director’s Interest Notice

	No. and class of securities to which interest relates	Up to 25 million shares to be issued under share purchase loan agreement upon achievement of the below performance hurdles: • Imugene share price to reach 5-day VWAP of $0.028, on or after 26 February 2016, Imugene to grant $150,000 loan to purchase 12.5 million new ordinary shares at a grant price of $0.012, subject to shareholder approval. • Imugene share price to reach 5-day VWAP of $0.0425, on or after 26 August 2016, Imugene to grant $150,000 loan to purchase 12.5 million new ordinary shares at a grant price of $0.012, subject to shareholder approval. The provision of the share purchase loan upon achievement of the above performance conditions provides performance based remuneration to Mr. Walker providing further financial incentive to improve the performance and value of the Company. The share purchase loan agreement further aligns his interests with the performance and value of the Company and the interests of shareholders.

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 3